Laser-induced damage growth of large-aperture fused silica optics under high-fluence 351 nm laser irradiation

Xiangxu Chai,Ping Li,Junpu Zhao,Guanzhong Wang,Deyan Zhu,Yilan Jiang,Bo Chen,Qihua Zhu,Bin Feng,Liquan Wang,Yukun Jing
DOI: https://doi.org/10.1016/j.ijleo.2020.165549
IF: 3.1
2021-01-01
Optik
Abstract:<p>Laser-induced damage (LID) of fused-silica optics is a key factor limiting the output energy of high-power laser facility. In this paper, we study the LID growth of a large-aperture fused silica wedged focus lens (WFL) and vacuum window (VW) at high-fluence 351 nm. Results show the damage sites number on both optics increases gradually with shots first, then tends to stabilize at the subsequent shots. Besides, the VW has much more damage sites and the damage size grows faster than that on the WFL. According to the damage morphology and growth behavior, the damage sites are mainly ascribed to the initial defects on surfaces. And the fluence variation may be responsible for their damage performance differences.</p>
optics
What problem does this paper attempt to address?
The text contains summaries of five different research abstracts, each exploring a different health-related topic. Below is a summary of the issues each abstract attempts to address: ### PIH1: Comparison of Unintended Pregnancy Rates with Different Oral Contraceptive Regimens - **Objective**: To compare the unintended pregnancy rates over one year among three different oral contraceptive regimens (84/7, 21/7, and 24/4). - **Results**: The pregnancy rate for the 84/7 regimen was significantly lower than for the 21/7 and 24/4 regimens. ### PIH2: Canadian Synagis Registry Database (2005-2010) - **Objective**: To evaluate the management of high-risk children receiving palivizumab for the prevention of respiratory syncytial virus (RSV) infection. - **Results**: Hospitalization rates were low, and no serious adverse events directly related to the drug were found. ### PIH3: RSV Hospitalization Rates in the Canadian Synagis Registry Database - **Objective**: To determine the hospitalization rates for respiratory illness (RI) and RSV infection among high-risk infants receiving palivizumab prophylaxis and compare these rates with data from other countries. - **Results**: Hospitalization rates varied among different groups but were generally lower compared to other international data. ### PIH4: Comparative Study of RSV Prophylaxis in Preterm Infants - **Objective**: To compare the effectiveness of palivizumab prophylaxis in preterm infants born at 32 to 35 weeks gestational age. - **Results**: Although preterm infants born before 32 weeks received more doses of palivizumab, the RSV hospitalization rates were similar between the two groups. ### PIH5: RSV Prophylaxis in Special Populations - **Objective**: To compare the usage and compliance of palivizumab prophylaxis in infants meeting standard prevention criteria versus those with underlying medical conditions. - **Results**: Infants with underlying medical conditions had higher hospitalization rates but slightly lower compliance. No serious adverse events directly related to the drug were found. These studies aim to optimize medical management and preventive measures through data analysis, thereby improving the quality of life for patients.